ATRA · XBRL financial data

Atara Biotherapeutics financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (ATRA's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024†Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	—	—	—	9	129	121
Research and development	245	282	273	225	151	37
General and administrative	64	79	72	51	40	26
Total operating expenses	309	361	344	—	—	—
Other operating income (expense)	—	—	—	0	2	3
Operating income (loss)	(309)	(340)	(281)	(276)	(83)	36
Interest expense	—	—	0	5	5	4
Other income (expense)	2	0	2	(0)	1	(0)
Income tax expense (benefit)	0	0	0	0	(0)	0
Net income (loss)	(307)	(340)	(228)	(276)	(85)	33
Earnings per share, basic USD per share	(4.15)	(3.63)	(2.24)	(2.61)	(11.41)	2.61
Earnings per share, diluted USD per share	(4.15)	(3.63)	(2.24)	(2.61)	(11.41)	2.57
Weighted average shares, basic millions of shares	74	94	102	106	7	13
Weighted average shares, diluted millions of shares	74	94	102	106	7	13

† Share count changed about 1/20 in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (ATRA's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024†Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	200	106	93	26	25	8
Short-term investments	300	265	150	26	17	0
Accounts receivable	1	1	40	34	1	1
Inventory	—	0	2	10	11	0
Prepaid and other current assets	21	12	—	—	—	—
Total current assets	523	385	295	102	65	12
Property and equipment, net	51	54	6	4	1	0
Right-of-use asset	12	26	68	55	40	7
Total assets	588	468	376	166	109	20
Accounts payable	7	17	7	4	4	0
Accrued liabilities	3	6	7	19	6	2
Total current liabilities	83	106	79	142	135	15
Lease liability, non-current	13	26	58	46	30	9
Total liabilities	126	189	250	265	206	59
Accumulated deficit	(1,125)	(1,465)	(1,693)	(1,969)	(2,055)	(2,022)
Total stockholders' equity	462	280	127	(99)	(97)	(39)
Total liabilities and equity	588	468	376	166	109	20
Common shares outstanding (cover page) millions of shares	84	93	96	119	6	8

† Share count changed about 1/20 in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (ATRA's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024†Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(307)	(340)	(228)	(276)	(85)	33
Stock-based compensation	51	54	54	45	27	10
Net cash from operating activities	(181)	(221)	(270)	(193)	(69)	(51)
Purchases of property and equipment	5	11	4	1	0	0
Net cash from investing activities	(121)	22	203	124	9	18
Proceeds from issuing common stock	69	99	22	2	9	1
Net cash from financing activities	428	104	53	2	59	16

† Share count changed about 1/20 in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Atara Biotherapeutics	3.2	0.6	(3.3)*	10.0M	3.0 quarters	Q2 FY26 10-QJun 30, 2026
CervoMed	22	0	(6.9)*	15.1M	3.6 quarters	Q2 FY26 10-QJun 30, 2026
BriaCell Therapeutics	9.9	not reported	(6)*	8.7M	3.4 quarters	Q4 FY26 10-KJul 31, 2026
Abvc Biopharma	0	not reported	(0.2)*	26.7M	0.4 quarters	Q2 FY26 10-QJun 30, 2026
Karyopharm Therapeutics	55	33	(25)*	22.7M	2.6 quarters	Q2 FY26 10-QJun 30, 2026
Annovis Bio	19	0*	(22)*	42.6M	0.9 quarters	Q2 FY26 10-QJun 30, 2026
Actuate Therapeutics	4.4	not reported	(4.4)*	24.0M	1.0 quarters	Q2 FY26 10-QJun 30, 2026
Grace Therapeutics	14	not reported	(3.2)	21.0M	4.3 quarters	Q1 FY27 10-QJun 30, 2026
Lite Strategy	5.7	not reported	(1.2)*	30.4M	4.9 quarters	Q4 FY26 10-KJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.